Literature DB >> 6951051

The modulation of human natural killer cell activity by prostaglandins.

A D Bankhurst.   

Abstract

Prostaglandins (PGs) have been implicated as a regulator of tumor growth in mice and humans. Since natural killer cell (NK) cytotoxicity may be an important component of immune surveillance against cancer, it is appropriate to study whether the amount of PGs produced by tumors may be sufficient to suppress NK activity. Accordingly, the effect of various PGs on the NK activity of human peripheral mononuclear cells was investigated. The percentage cytotoxicity was measured by the release of Cr51 from labeled K562 and other target cells. At very high concentrations of PG (10(-6) M), suppression was seen with PGE2, PGD2, PGA2, and PGF2 alpha. However, at concentrations of PG in the physiologic range (10(-8) M), significant suppression was seen with PGE2 and PGD2 only. The percentage suppression with PGE2 ranged from 77% to 9.5% over a range of concentrations from 10(-5) to 10(-9) M (45% at 10(-8) M). Significant suppression was observed at 10(-8) M PGE2 with 4 different targets and at effector:target ratios varying from 50:1 to 12.5:1. To assess whether the suppressive effect of PGE2 was directed at the effector and/or target cell, K562 cells or effector cells were pretreated with PGE2. Significant suppression was seen with effector cell pretreatment but not with target cell pretreatment. Finally, the suppressive effects of supernatants obtained from tumor cell lines (polyoma virus-transformed murine fibroblast cell line, PY3T3) was determined. The marked suppressive effect of the supernatant could be attributed to its content of PGE. Thus, it appears that the production of PGE by tumor cells may be an important modulator of human NK activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6951051

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  31 in total

Review 1.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.

Authors:  N Lahat; B Alexander; D R Levin; B Moskovitz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Prostaglandin E2 as a Regulator of Immunity to Pathogens.

Authors:  Giovanny J Martínez-Colón; Bethany B Moore
Journal:  Pharmacol Ther       Date:  2017-12-22       Impact factor: 12.310

4.  In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins.

Authors:  Ella Rosenne; Liat Sorski; Lee Shaashua; Elad Neeman; Pini Matzner; Ben Levi; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2013-12-12       Impact factor: 7.217

Review 5.  Regulation of immune responses by prostaglandin E2.

Authors:  Pawel Kalinski
Journal:  J Immunol       Date:  2012-01-01       Impact factor: 5.422

6.  Restoration of immune responses of aging hamsters by treatment with isoprinosine.

Authors:  K Y Tsang; H H Fudenberg; M J Gnagy
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

Review 7.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

8.  Natural killer cell and islet killer cell activities in type 1 (insulin-dependent) diabetes.

Authors:  K Negishi; N Waldeck; G Chandy; B Buckingham; A Kershnar; L Fisher; S Gupta; M A Charles
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

9.  Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

Authors:  W L Sibbitt; P M Mathews; A D Bankhurst
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

10.  Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin.

Authors:  M Sato; T Narisawa; M Sano; T Takahashi; A Goto
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.